Cagrilintide + semaglutide

Status

In trials. Investigational co-formulation. An FDA decision is expected in late 2026 — the next major one on the calendar.

What it is

Two peptides in one pen: semaglutide (the GLP-1 arm) and cagrilintide (an amylin analogue — amylin is the hormone co-released with insulin that signals fullness through a different pathway than GLP-1).

What published research measured

The REDEFINE Phase 3 program reported weight-loss results that came in below early Phase 2 expectations, a useful reminder that trial-phase signals routinely shrink.

Source

Novo Nordisk REDEFINE program announcements

Sources

• ObesityWeek presentations are scheduled for November 14 to 17 (2026-11-14)